Upsher-Smith launches famotidine for oral suspension
MAPLE GROVE, Minn. – Upsher-Smith has announced the recent launch of famotidine for oral suspension, USP. The famotidine oral suspension market had U.S. sales of approximately $73 million for the 12 months ending June 2023 according to IQVIA.